NASDAQ:CYCC - Cyclacel Pharmaceuticals Stock Price, Forecast & News

Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."

Shares of Cyclacel Pharmaceuticals reverse split before market open on Tuesday, May 31st 2016. The 1-12 reverse split was announced on Friday, May 27th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 27th 2016. An investor that had 100 shares of Cyclacel Pharmaceuticals stock prior to the reverse split would have 8 shares after the split.

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) released its quarterly earnings results on Thursday, August, 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.12) by $0.04. View Cyclacel Pharmaceuticals' Earnings History.

Cyclacel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for Cyclacel Pharmaceuticals.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cyclacel Pharmaceuticals.

Media headlines about CYCC stock have been trending negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cyclacel Pharmaceuticals earned a news impact score of -2.7 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Cyclacel Pharmaceuticals.

Cyclacel Pharmaceuticals saw a decline in short interest in January. As of January 31st, there was short interest totalling 298,900 shares, a decline of 30.1% from the January 15th total of 427,900 shares. Based on an average daily trading volume, of 249,400 shares, the days-to-cover ratio is currently 1.2 days. Currently, 1.8% of the company's shares are short sold. View Cyclacel Pharmaceuticals' Current Options Chain.

Some companies that are related to Cyclacel Pharmaceuticals include IntelGenx Technologies (IGXT), resTORbio (TORC), Vascular Biogenics (VBLT), Zafgen (ZFGN), Hoth Therapeutics (HOTH), Acer Therapeutics (ACER), PLx Pharma (PLXP), SUMMIT THERAPEU/S (SMMT), Adamis Pharmaceuticals (ADMP), Humanigen (HGEN), Annovis Bio (ANVS), Forward Pharma A/S (FWP), Merrimack Pharmaceuticals (MACK), Pharmaxis (PXSLY) and Iterum Therapeutics (ITRM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include McEwen Mining (MUX), NovaBay Pharmaceuticals (NBY), Exelixis (EXEL), Inovio Pharmaceuticals (INO), Novavax (NVAX), Celldex Therapeutics (CLDX), Synergy Pharmaceuticals (SGYP), AcelRx Pharmaceuticals (ACRX), CTI BioPharma (CTIC) and Immunomedics (IMMU).

Cyclacel Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (7.38%), Raymond James Financial Services Advisors Inc. (0.35%) and Virtu Financial LLC (0.29%). View Institutional Ownership Trends for Cyclacel Pharmaceuticals.

CYCC stock was sold by a variety of institutional investors in the last quarter, including Raymond James Financial Services Advisors Inc.. View Insider Buying and Selling for Cyclacel Pharmaceuticals.

CYCC stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Virtu Financial LLC. View Insider Buying and Selling for Cyclacel Pharmaceuticals.

Shares of CYCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CYCC stock can currently be purchased for approximately $0.71.

Cyclacel Pharmaceuticals has a market capitalization of $12.27 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-7,290,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Cyclacel Pharmaceuticals employs 14 workers across the globe.View Additional Information About Cyclacel Pharmaceuticals.

The official website for Cyclacel Pharmaceuticals is http://www.cyclacel.com/.

Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The biotechnology company can be reached via phone at 908-517-7330 or via email at [email protected]